ArticleDiscover oncology2026
CST4 promotes EMT and tumor progression in ovarian cancer via Wnt/β-catenin signaling.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing the frontiers of ovarian cancer therapy: a comprehensive synthesis of emerging cell death paradigms.Oncology reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOvarian cancer (OC) is one of the most lethal gynecologic malignancies, largely due to late diagnosis, high metastatic potential, and chemoresistance. Cystatin S (CST4) has been implicated in the tumor progression of several cancers, but its role in OC remains unclear. This study aims to investigate the expression, clinical significance, and functional role of CST4 in OC, particularly its involvement in epithelial-mesenchymal transition (EMT) via the Wnt/β-catenin signaling pathway.
methodsImmunohistochemistry (IHC) was performed on 102 °C tissues and 20 normal ovarian tissues to assess CST4 expression. Through Kaplan-Meier analysis and Cox regression analysis, the association between CST4 expression and clinical pathological features, prognosis and survival outcomes was investigated. To investigate the functional role of CST4, small interfering RNA (siRNA) was used to silence CST4 expression in HEY and HO-8910 cell lines. Following CST4 knockdown, cell proliferation was assessed using CCK-8 assays and colony formation assays, while migratory and invasive capacities were evaluated through wound healing and transwell invasion assays, respectively. In addition, western blotting was employed to examine the expression of epithelial-mesenchymal transition (EMT)-related markers and key proteins involved in the Wnt/β-catenin signaling pathway.
resultsCompared with normal ovarian tissue, the expression of CST4 in OC tissues was significantly increased, and it was associated with more advanced FIGO stages, elevated CA125 levels, platinum resistance, and poor prognosis. High CST4 expression was identified as an independent prognostic factor for reducing overall and progression-free survival. Functional assays showed that CST4 knockdown suppressed OC cell proliferation, migration, and invasion. Mechanistically, CST4 silencing inhibited the Wnt/β-catenin signaling pathway and reversed the expression of EMT markers.
conclusionsCST4 is a novel oncogenic regulator in OC that promotes EMT and tumor aggressiveness via the Wnt/β-catenin signaling pathway. It may serve as an independent prognostic biomarker and potential therapeutic target for OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.